Penumbra, Inc.(PEN) Stock Research - Grey Stern Research
Loading...

Penumbra, Inc. (PEN) Stock Analysis

$203.53 (0.99%)

PEN Financial Performance


Use the table below to view Penumbra, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q4 - 2023

Metric Value Ranking among Peers
Price $201.53 -
52 Week Low $180.93 -
52 Week High $348.67 -
Market Cap $7.8 Billion 4/15
Gross Margin 66% 7/15
Profit Margin 19% 4/15
EBITDA margin 11% 5/15
Q4 - 2023 Revenue $284.7 Million 7/15
Q4 - 2023 Earnings $54.2 Million 5/15
Q4 - 2023 Free Cash Flow $32.6 Million 5/15
Trailing 4 Quarters Revenue $1.1 Billion 7/15
Trailing 4 Quarters Earnings $91.0 Million 5/15
Quarterly Earnings Growth 1298% 1/15
Annual Earnings Growth 3198% 2/15
Quarterly Revenue Growth 29% 4/15
Annual Revenue Growth 23% 5/15
Cash On Hand $167.5 Million 7/15
Short Term Debt $13.4 Million 6/15
Long Term Debt $220.9 Million 10/15

Penumbra, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Penumbra, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 85.89 1/15
PS 7.38 5/15
PB 6.63 8/15
PC 46.64 7/15
Liabilities to Equity 0.32 13/15
ROA 0.06 5/15
ROE 0.08 6/15
Current Ratio 4.12 3/15
Quick Ratio 0.77 4/15
Long Term Debt to Equity 0.19 12/15
Debt to Equity 0.20 12/15
Burn Rate -3.99 12/15
Cash to Cap 0.02 8/15
CCR 0.60 8/15
EV to EBITDA 248.62 5/15
EV to Revenue 7.44 5/15

Company Details

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

CEO: Mr. Adam Elsesser

Website: https://www.penumbrainc.com

Address: 1 Penumbra Alameda, CALIFORNIA

Exchange: New York Stock Exchange

Industry: Medical Devices

Penumbra, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Penumbra, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Tandem Diabetes Care, Inc. TNDM $3.1 Billion
DexCom, Inc. DXCM $52.2 Billion
LivaNova PLC LIVN $3.4 Billion
Insulet Corporation PODD $13.1 Billion
Masimo Corporation MASI $6.6 Billion
iRhythm Technologies, Inc. IRTC $2.9 Billion
Integer Holdings Corporation ITGR $4.1 Billion
CONMED Corporation CNMD $2.3 Billion
Heska Corporation HSKA $1.3 Billion
Inspire Medical Systems, Inc. INSP $4.6 Billion
InMode Ltd. INMD $1.6 Billion
ShockWave Medical, Inc. SWAV $12.4 Billion
TransMedics Group, Inc. TMDX $4.5 Billion
Inari Medical, Inc. NARI $2.7 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
PEN Income Statements
Quarter Year Revenue Earnings
Q4 2023 $ 284.7 Million $54.2 Million
Q3 2023 $ 270.9 Million $9.2 Million
Q2 2023 $ 261.5 Million $19.0 Million
Q1 2023 $ 241.4 Million $8.6 Million
Q4 2022 $ 221.2 Million $3.9 Million
Q3 2022 $ 213.7 Million -$2.3 Million
Q2 2022 $ 208.3 Million -$3.7 Million
Q1 2022 $ 203.9 Million $79,000

View All

PEN Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q4 2023 $167.5 Million $1.6 Billion $234.3 Million $1.2 Billion
Q3 2023 $100.8 Million $1.5 Billion $228.8 Million $1.1 Billion
Q2 2023 $114.2 Million $1.4 Billion $231.3 Million $1.1 Billion
Q1 2023 $94.7 Million $1.4 Billion $233.5 Million $1.0 Billion
Q4 2022 $69.9 Million $1.4 Billion $235.8 Million $998.9 Million
Q3 2022 $54.8 Million $1.3 Billion $217.5 Million $973.8 Million
Q2 2022 $58.2 Million $1.3 Billion $219.9 Million $970.0 Million
Q1 2022 $68.2 Million $1.3 Billion $219.0 Million $959.3 Million

View All

PEN Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q4 2023 $32.6 Million -$3.6 Million $66.7 Million
Q3 2023 $0 $0 $0
Q2 2023 $0 $0 $0
Q1 2023 $9.2 Million -$3.9 Million $24.8 Million
Q4 2022 -$2.2 Million -$3.6 Million $15.0 Million
Q3 2022 $0 $0 $0
Q2 2022 -$44,006 -$4,431 -$68.1 Million
Q1 2022 -$9.5 Million -$5.0 Million $8.8 Million

View All